These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23774633)

  • 1. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML.
    Takahashi K; Jabbour E; Wang X; Luthra R; Bueso-Ramos C; Patel K; Pierce S; Yang H; Wei Y; Daver N; Faderl S; Ravandi F; Estrov Z; Cortes J; Kantarjian H; Garcia-Manero G
    Leukemia; 2013 Oct; 27(10):2081-3. PubMed ID: 23774633
    [No Abstract]   [Full Text] [Related]  

  • 2. Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia.
    Meggendorfer M; de Albuquerque A; Nadarajah N; Alpermann T; Kern W; Steuer K; Perglerová K; Haferlach C; Schnittger S; Haferlach T
    Haematologica; 2015 Dec; 100(12):e487-90. PubMed ID: 26294738
    [No Abstract]   [Full Text] [Related]  

  • 3. Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features.
    Wang SA; Jabbar K; Lu G; Chen SS; Galili N; Vega F; Jones D; Raza A; Kantarjian H; Garcia-Manero G; McDonnell TJ; Medeiros LJ
    Leukemia; 2010 Apr; 24(4):740-7. PubMed ID: 20072149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.
    Badar T; Patel KP; Thompson PA; DiNardo C; Takahashi K; Cabrero M; Borthakur G; Cortes J; Konopleva M; Kadia T; Bohannan Z; Pierce S; Jabbour EJ; Ravandi F; Daver N; Luthra R; Kantarjian H; Garcia-Manero G
    Leuk Res; 2015 Dec; 39(12):1367-74. PubMed ID: 26547258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.
    Rocquain J; Carbuccia N; Trouplin V; Raynaud S; Murati A; Nezri M; Tadrist Z; Olschwang S; Vey N; Birnbaum D; Gelsi-Boyer V; Mozziconacci MJ
    BMC Cancer; 2010 Aug; 10():401. PubMed ID: 20678218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia.
    Bains A; Luthra R; Medeiros LJ; Zuo Z
    Am J Clin Pathol; 2011 Jan; 135(1):62-9. PubMed ID: 21173125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trisomy 11 as an isolated abnormality in acute myeloid leukemia is associated with unfavorable prognosis but not with an NPM1 or KIT mutation.
    Alseraye FM; Zuo Z; Bueso-Ramos C; Wang S; Medeiros LJ; Lu G
    Int J Clin Exp Pathol; 2011 Apr; 4(4):371-7. PubMed ID: 21577323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia.
    Daver N; Strati P; Jabbour E; Kadia T; Luthra R; Wang S; Patel K; Ravandi F; Cortes J; Qin Dong X; Kantarjian H; Garcia-Manero G
    Am J Hematol; 2013 Jan; 88(1):56-9. PubMed ID: 23115106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Han X; Medeiros LJ; Zhang YH; You MJ; Andreeff M; Konopleva M; Bueso-Ramos CE
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S30-8. PubMed ID: 27155969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
    Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
    Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML.
    Haferlach C; Bacher U; Haferlach T; Dicker F; Alpermann T; Kern W; Schnittger S
    Leukemia; 2011 May; 25(5):874-7. PubMed ID: 21283084
    [No Abstract]   [Full Text] [Related]  

  • 12. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.
    Shih LY; Huang CF; Wang PN; Wu JH; Lin TL; Dunn P; Kuo MC
    Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome.
    Shih LY; Lin TL; Wang PN; Wu JH; Dunn P; Kuo MC; Huang CF
    Cancer; 2004 Sep; 101(5):989-98. PubMed ID: 15329908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prognostic Ability of RAS Pathway-Related Gene Mutations in Patients with Myeloid Neoplasms Treated with Hypomethylating Agents.
    Park HS; Son BR; Shin KS; Byeon S; Kim HK; Yang Y; Jeong Y; Han HS; Lee KH; Kwon J
    Acta Haematol; 2021; 144(6):649-659. PubMed ID: 34233332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
    Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
    Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of FLT3-ITD Mutation on de Novo MDS in Chinese Population.
    Xu F; Han R; Zhang J; Li Z; Wang J; Chu XL; Yu JQ; Wang C; Tao T; Shen HJ; Chen SN; Wu DP; Liu SB; Qiu QC; Xue SL
    Clin Lymphoma Myeloma Leuk; 2019 Feb; 19(2):e107-e115. PubMed ID: 30555035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts.
    Blau O; Baldus CD; Hofmann WK; Thiel G; Nolte F; Burmeister T; Türkmen S; Benlasfer O; Schümann E; Sindram A; Molkentin M; Mundlos S; Keilholz U; Thiel E; Blau IW
    Blood; 2011 Nov; 118(20):5583-92. PubMed ID: 21948175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.
    Al-Kali A; Quintás-Cardama A; Luthra R; Bueso-Ramos C; Pierce S; Kadia T; Borthakur G; Estrov Z; Jabbour E; Faderl S; Ravandi F; Cortes J; Tefferi A; Kantarjian H; Garcia-Manero G
    Am J Hematol; 2013 May; 88(5):365-9. PubMed ID: 23512829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia.
    Bacher U; Haferlach T; Kern W; Haferlach C; Schnittger S
    Haematologica; 2007 Jun; 92(6):744-52. PubMed ID: 17550846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of KRAS and NRAS Gene Mutations in Arab Asian Children With Acute Leukemia: High Frequency of RAS Mutations in Acute Lymphoblastic Leukemia.
    Al-Kzayer LF; Sakashita K; Al-Jadiry MF; Al-Hadad SA; Ghali HH; Uyen le TN; Liu T; Matsuda K; Abdulkadhim JM; Al-Shujairi TA; Matti ZI; Sughayer MA; Rihani R; Madanat FF; Inoshita T; Kamata M; Koike K
    Pediatr Blood Cancer; 2015 Dec; 62(12):2157-61. PubMed ID: 26222068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.